Leheny A. Rachel

CEO Rachel Leheny bought 1,000 shares of CALC at $3.40 on 2025-07-21, adding to recent cluster of insider purchases.

Rachel Leheny, CEO of CalciMedica, purchased 1,000 shares at $3.40, increasing her holdings by 40.0% to 3,500 shares post-transaction. This buy follows a purchase by the same insider just 7 days prior (2025-07-14) and occurs as part of a broader cluster with 2 other insiders buying within the past 14 days. The stock has recovered sharply over 30 days (+112.8%) and 90 days (+129.6%) from depressed levels, though it remains 34.2% below its 52-week high of $5.30. At the same ticker, Leheny's prior buy on 2023-11-06 delivered +78.8% over 90 days and the 2023-11-07 purchase delivered +52.7%, but the 2024-11-01 buy declined -32.3% at the 90-day mark—a mixed record. The company remains unprofitable with net income of $-5,042,000.00 over its most recent full fiscal year, and the market cap stands at $48,762,245.10. The timing of multiple insiders buying within two weeks, combined with the stock's steep recent climb, merits investor attention to whether this represents genuine conviction or opportunistic accumulation at a temporarily inflated price level after a recovery spike.

CEO Leheny buys 2,500 shares of CALC at $2.47; stock now $2.05, -61.3% from 52-week high. 2 other insiders also bought in 14 days.

Rachel Leheny, as CEO, purchased 2,500 shares at $2.47 on 2025-07-14, establishing an initial position. At the current price of $2.05, her entry is underwater by approximately 17%, and the stock remains -61.3% from its 52-week high of $5.30. Her same-ticker trade history at CALC shows mixed outcomes: 3 of 5 prior buys did achieve positive 90-day returns (including a +117.5% gain on 2023-11-03), but the most recent buy on 2024-11-01 declined -32.3% over 90 days. The company posted a net loss of $-5,042,000.00 and remains unprofitable, raising questions about fundamental support for a recovery. The cluster pattern—with 2 other insiders also purchasing within the past 14 days—suggests coordinated confidence at current levels, though this must be weighed against the steep drawdown from the 52-week high and ongoing losses.

CALC CEO Leheny buys 20,000 shares at $3.75; joined 4 other insiders in cluster buy amid -52.8% 52-week drawdown, unprofitable state.

Leheny A. Rachel (CEO) purchased 20,000 shares at $3.75 on 2024-11-01, expanding her holdings by 18.0% to 130.9K shares total. The transaction is notable for two interlocking signals: (1) cluster activity—4 other insiders bought within the past 14 days—suggesting coordinated confidence at a depressed entry point; and (2) the insider's own historical accuracy. Her cross-ticker track record shows 100.00% 90-day win rate with average 90-day returns of 83.0% across 4 prior buys. At this specific ticker, her prior 3 measurable trades all delivered positive 90-day returns (37.9%, 78.8%, and 117.5%), establishing a pattern of well-timed purchases. The stock is now -52.8% from its 52-week high and trading 17 days post-purchase at prices below her entry. The company remains unprofitable with a $-4.0M net loss, so this is not a value-driven recovery position but rather a conviction accumulation during extended weakness.

CALC CEO Rachel Leheny bought 1,000 shares at $4.19; prior 3 same-ticker buys timed perfectly (90d range +1.4% to +117.5%); cluster pattern with 2 other insiders in 14 days.

CEO Rachel Leheny purchased 1,000 shares at $4.19, extending her holdings to 110,926 shares. Her track record at this ticker is notably strong: three prior buys in November 2023 posted 90-day returns of +1.4%, +78.8%, and +117.5%, with a 100% timing success rate at the 90-day mark. The current purchase occurs as the stock trades at $4.21, positioned 43.4% below its 52-week high of $7.44, suggesting the timing follows a familiar pattern of accumulation during weakness. The transaction is part of a broader cluster, with two other insiders also buying within the past 14 days, indicating alignment among the leadership team. However, context matters: the company posted a net loss of $4.0M in its most recent full fiscal year and carries a market cap of $45.3M, so the buy occurs against fundamentally challenged operating metrics.